Prognostic role of PD-L-ligands in patients with Hodgkin’s lymphoma

Novosad O., Skripets Т.V., Skachkova O.V., Khranovska N.M., Kriachok I.A.

Резюме. Over the last 20 years a lot of immunotherapy cancer researcher is conducted. Immune checkpoints represent inhibitory mechanisms system which regulates the activation of the immune response. As the major part of checkpoints are based on the ligand-receptor interactions, the main strategy of antitumor therapy is developing and using of new monoclonal antibodies. Programmed cell death ligand 1 (PD-1) and its ligands (PD-L1/2) plays a major role in tumor-induced immune suppression and highly appreciated on their use in the development of immunotherapy drugs.
Follow us on social media:
No Comments » Add your
Leave a comment